Biovica, active in cancer diagnostics, will host a Capital Markets Day on Tuesday May 17, 2022, from 14.00 to 16.30.
Biovica is approaching market launch of DiviTum®TKa in the US for the monitoring of metastatic breast cancer treatments. Today, DiviTum®TKa is sold to pharmaceutical companies and academic institutions for use in clinical studies. Following FDA approval expected in the third quarter 2022, the large market for patient monitoring will be available.
Some of the speakers at the Capital Markets Day:
Warren Cresswell, President Americas, will give deeper insight into the planned upcoming launch of DiviTum®TKa in the US.
Amy Williams, Head of Clinical Development & Medical Affairs, on the Clinical and Medical affairs support of the launch.
Henrik Winther, SVP Business Development, on Pharma Collaborations.
The Capital Markets Day will take place in the room Turbine at GT30, Grev Turegatan 30, Stockholm on May 17, 2022, at 14.00 to 16.30. The event will also be broadcasted at: https://tv.streamfabriken.com/biovica-international-cmd-2022
To participate in person please register at: https://financialhearings.com/event/44233/register/live_event
To participate online, no advance registration is needed.
Questions can be sent in advance or during the event to email@example.com
This information was distributed by MFN https://www.mfn.se/